Topics

As 'big three' oncology meds lose sales, Roche looks to file subcutaneous breast cancer combo

06:50 EDT 13 Sep 2019 | pharmaphorum

A subcutaneous formulation of Roche’s Perjeta and Herceptin breast cancer drugs works as well as an original intravenous (IV) version, a study has shown. Roche’s Genentech unit is developing a subcutaneous version of the fixed-dose combination for...

Original Article: As 'big three' oncology meds lose sales, Roche looks to file subcutaneous breast cancer combo

NEXT ARTICLE

More From BioPortfolio on "As 'big three' oncology meds lose sales, Roche looks to file subcutaneous breast cancer combo"

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...